Harrow Health, Inc. Q1 2026 Earnings Call Summary

Harrow Health, Inc. Q1 2026 Earnings Call Summary - Moby

Strategic Performance Attribution and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management attributed the Q1 revenue shortfall to a discrete $8 million gross-to-net modeling dynamic for VEVYE, where a surge in high-deductible patient volume outpaced initial financial assumptions. Underlying demand for VEVYE remains robust, with new prescriptions growing 25% sequentially despite a broader branded dry eye market that declined 18% during the same period. The company completed a major commercial expansion, doubling the VEVYE sales force and tripling the TRIESENCE team to convert accelerating demand into sustained revenue. IHEEZO demand continues to build in the retina market, with management focusing on transitioning volume from the ASC setting to the more durable in-office procedural market. Operational issues in the Access+ compounding business related to prior inventory constraints have been resolved, positioning the segment to return to a growth trajectory. Management emphasizes that the business has shifted from an infrastructure-building phase to an execution phase focused on 'economic accomplishment' and profitability.

2026 Outlook and Strategic Catalysts

Reiterated full-year 2026 revenue guidance of $350 million to $365 million, supported by a significant expected step-up in second-half performance. VEVYE net pricing is expected to improve by approximately 30% following mid-April business rule adjustments that capped co-pay buydowns for high-deductible patients. The July 1 launch of a permanent J-code for IOPIDINE 1% is expected to unlock a market of 1.5 million annual laser procedures by aligning physician incentives with reimbursement. IHEEZO is positioned for a 'step change' in Q3 and Q4 driven by a 20% to 25% improvement in net pricing and the introduction of new multi-unit packaging. The G-MELT NDA submission is targeted for Q1 2027, with management viewing it as a potential top-selling asset capable of disrupting standard procedural sedation.

Structural Shifts and Risk Factors

The transition of IHEEZO out of the 'pass-through' reimbursement status in ASCs has led to a strategic pivot toward the in-office setting where coverage is nearly 95%. Management flagged a standard industry lag in claims reporting as the reason the VEVYE mix shift was not fully confirmed until mid-April. The commercial launch of BYOOVIZ on July 1 and the trade launch of BYQLOVI in Q3 represent new high-margin revenue streams for the second half of the year. Harrow is initiating a unified corporate initiative to achieve $250 million in quarterly revenue by the end of 2027.

Story Continues

Q&A Session Summary

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

VEVYE gross-to-net adjustments and pricing sustainability

Management explained that CVS patients had out-of-pocket buydowns 40% higher than other covered patients, leading to the $8 million revenue reduction. New business rules implemented in April have already shown 'higher highs and higher lows' in daily prescription data with negligible impact on patient access.

IHEEZO adoption catalysts and ASC volume replacement

While ASC volume is expected to go to zero, management expects to fully replace that unit volume with in-office use cases by year-end. Growth will be supported by the first retina-specific clinical data reading out in July and the launch of a 5-pack presentation tailored for high-volume practices.

Sales force expansion strategy and specialty product focus

The 100 new hires include a 'specialty team' dedicated to underappreciated assets like VERKAZIA and NATACYN, which previously lacked promotional support. Sales incentives have been restructured to prioritize commercially covered prescriptions over cash-pay consignment to maximize economic value.

View Comments